205 related articles for article (PubMed ID: 35032591)
1. Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection.
Fishbane S; Hirsch JS; Nair V
Am J Kidney Dis; 2022 Apr; 79(4):480-482. PubMed ID: 35032591
[No Abstract] [Full Text] [Related]
2. Three more points about Paxlovid for covid-19.
Phizackerley D
BMJ; 2022 Jun; 377():o1397. PubMed ID: 35672048
[No Abstract] [Full Text] [Related]
3. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
Prikis M; Cameron A
Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
[TBL] [Abstract][Full Text] [Related]
4. Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.
Sun F; Lin Y; Wang X; Gao Y; Ye S
Lancet Infect Dis; 2022 Sep; 22(9):1279. PubMed ID: 35843259
[No Abstract] [Full Text] [Related]
5. African clinical trial denied access to key COVID drug Paxlovid.
Ledford H; Maxmen A
Nature; 2022 Apr; 604(7906):412-413. PubMed ID: 35379975
[No Abstract] [Full Text] [Related]
6. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
[TBL] [Abstract][Full Text] [Related]
7. Public Health Impact of Paxlovid as Treatment for COVID-19, United States.
Bai Y; Du Z; Wang L; Lau EHY; Fung IC; Holme P; Cowling BJ; Galvani AP; Krug RM; Meyers LA
Emerg Infect Dis; 2024 Feb; 30(2):262-269. PubMed ID: 38181800
[TBL] [Abstract][Full Text] [Related]
8. Experience Using Paxlovid for Patients With Coronavirus Disease 2019 in a Resource-Limited Emergency Department.
Nene RV; Navarro MR; Tomaszewski CA; Lafree A
Ann Emerg Med; 2022 Oct; 80(4):382-383. PubMed ID: 36153054
[No Abstract] [Full Text] [Related]
9. Paxlovid-Tacrolimus Drug-Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19.
Berar Yanay N; Bogner I; Saker K; Tannous E
Clin Drug Investig; 2022 Aug; 42(8):693-695. PubMed ID: 35816278
[No Abstract] [Full Text] [Related]
10. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
[TBL] [Abstract][Full Text] [Related]
11. A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections.
Hao X; Bao Z; Dai R; Wu X; Li X; Zhang M; Li H; Xu L; Qiao P; Liu X; Hu W; Zhang Z; Fang J; Zhou M; Wang W; Qu J
Front Med; 2024 Feb; 18(1):169-179. PubMed ID: 37978164
[TBL] [Abstract][Full Text] [Related]
12. New Data on Paxlovid Reported.
Rosenberg K
Am J Nurs; 2022 Oct; 122(10):59. PubMed ID: 36136030
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19.
Zhang H; Xiaojiao T; Chen J; Zhang Z; Wang C; Shi H; Li Y; Li J; Kang Y; Jin X; Liao X
BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38599779
[TBL] [Abstract][Full Text] [Related]
14. In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery.
Wang Z; Yang L
J Med Virol; 2022 May; 94(5):1766-1767. PubMed ID: 34936106
[No Abstract] [Full Text] [Related]
15. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
16. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
Parums DV
Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
[TBL] [Abstract][Full Text] [Related]
17. Network Pharmacology and Bioinformatics Analysis Identifies Potential Therapeutic Targets of Paxlovid Against LUAD/COVID-19.
Zhang W; Yang Z; Zhou F; Wei Y; Ma X
Front Endocrinol (Lausanne); 2022; 13():935906. PubMed ID: 36157452
[TBL] [Abstract][Full Text] [Related]
18. Covid-19: What is the evidence for the antiviral Paxlovid?
Extance A
BMJ; 2022 Apr; 377():o1037. PubMed ID: 35477536
[No Abstract] [Full Text] [Related]
19. COVID-19 update: Prescription of Paxlovid by pharmacists.
Med Lett Drugs Ther; 2022 Aug; 64(1656):e124. PubMed ID: 35921075
[No Abstract] [Full Text] [Related]
20. Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'.
Zhou XX; Ji HJ
Eur J Hosp Pharm; 2024 Feb; 31(2):178-179. PubMed ID: 36737228
[No Abstract] [Full Text] [Related]
[Next] [New Search]
